Fermenta Receives FSSAI Approval for Vitamin D3 (Cholecalciferol) - Plant Source (VITADEE Green®) for Health Supplements, Nutraceuticals and Food Products

▴ Mr. Prashant Nagre, Managing Director, Fermenta Biotech Limited
Reinforces Fermenta’s leadership in science-backed Vitamin D3 solutions and its commitment to addressing India’s widespread Vitamin D deficiency

Mumbai, 06 July 2026: Fermenta Biotech Limited, India’s leading manufacturer of premium-grade APIs, intermediates, and nutritional premixes for the global markets, today announced that its Vitamin D3 (Cholecalciferol) - Plant Source (VITADEE Green®) has received approval from the Food Safety and Standards Authority of India (FSSAI) for use as an ingredient in Health Supplements, Nutraceuticals and Food Products.

The approval allows Indian food and supplement manufacturers to use VITADEE Green® in fortified staple foods, food and beverages, dietary supplements and nutraceuticals, addressing one of the most pressing gaps in the country’s nutritional landscape. Studies estimate that a large percentage of the Indian population has suboptimal Vitamin D levels, a deficiency increasingly linked to urbanisation, indoor lifestyles and limited sun exposure despite the country’s geography.

Comment from Prashant Nagre – Managing Director

“Vitamin D deficiency remains a widespread public health concern in India, and the demand for sustainable nutrition continues to grow rapidly. The FSSAI approval allows us to bring VITADEE Green® directly to Indian food fortification and nutraceutical manufacturers, helping bridge the nutrition gap for the country’s large population.

As one of the first Indian companies to develop and patent a sustainable, scalable and affordable plant-source Vitamin D3 process, we are well placed to tackle the deficiency at a national level. Developed and manufactured in India, VITADEE Green® also supports the Make in India vision by offering a self-reliant domestic option for Indian formulators. Crucially, VITADEE Green® offers Indian formulators the superior D3 form in a fully plant-sourced format, rather than the Vitamin D2 they have often had to settle for. This is a meaningful step in our commitment to delivering differentiated, science-validated and sustainable solutions that create lasting value for our customers and for society.”

For India’s vegetarian consumers, who have had limited access to a plant-source Vitamin D3, the development brings a domestically manufactured, regulatory-cleared option to the market. It also supports the broader national objective of addressing Vitamin D deficiency through food fortification, an area where regulators have increasingly favoured plant-based sources.

About Fermenta

Fermenta Biotech Limited (www.fermentabiotech.com) delivers best-in-class, science-validated nutritional ingredients, green chemistry and environmental solutions across pharmaceuticals, dietary supplements, food & beverage, veterinary, and animal nutrition industries. Our state-of-the-art manufacturing facilities located at Kullu (Himachal Pradesh), Dahej (Gujarat), and Tirupati (Andhra Pradesh), supported by the R&D Excellence Centre at Thane (near Mumbai) drive Fermenta’s comprehensive portfolio of premium vitamins, nutritional premixes and ingredients that exceed the unique needs and stringent regulatory standards of over 400 discerning customers in more than 60 countries. With decades of expertise at global-scale complex manufacturing, Fermenta also provides research-based custom solutions in green chemistry, APIs & intermediates, and environmental solutions.

Safe Harbour Statement

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, market opportunities, competitive positioning, regulatory approvals, commercialization potential, the progress and results of research and development, potential project characteristics, project potential, and target dates for project related issues are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements due to various factors including market conditions, regulatory changes, competitive dynamics, and other business risks. Fermenta Biotech Limited assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions, or other factors, except as and when required by applicable law.

Contact

Varadvinayak Khambete | varadvinayak.khambete@fermentabiotech.com

Tags : #

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-



Trending Now

Nanavati Max Hospital Hosts Max Cancer Congress 2026, Bringing Together Oncology Experts to Explore the Future of Cancer Care October 01, 2026
Dhiya Fertility and Maternity Center Performs Tamil Nadu’s First Robot-Assisted Fertility Procedure; 37-Year-Old Woman Delivers Healthy Baby GirlOctober 01, 2026
Habuild’s “Are You Still Awake?” Campaign Encourages India to Switch Off, Sleep on Time and Not Take Everything to Heart October 01, 2026
CoinSwitch Turns Profitable in FY26 as Revenue Surges 150% to ₹324 CrOctober 01, 2026
Mega CPR Training: Baby Memorial Hospital Vadakara enters Asia and India Book of RecordsOctober 01, 2026
Supertails vaccinates 300 dogs and cats against rabies across Bengaluru in a three-day World Rabies Day drive October 01, 2026
Why Continuity of Care Matters When Patients Move Between Health FacilitiesOctober 01, 2026
Building Stronger Referral Pathways Between Primary Care and Specialist ServicesOctober 01, 2026
How Can Diabetes and High Blood Pressure Quietly Lead to Kidney Failure?September 30, 2026
Apollo Hospitals’ “My Hands Are Ready” Sets World Record Title with 61,221 CPR Pledges in 30 DaysSeptember 30, 2026
How Medical Device Trials and Validation Shape Safer Healthcare Innovation in IndiaSeptember 30, 2026
Medical Device Safety in India: What Patients Should Know About Recalls and AlertsSeptember 30, 2026
Smart Implants: How Connected Devices Could Transform Follow-Up Care in IndiaSeptember 30, 2026
Single-Use Medical Devices: Innovation, Cost and Sustainability in Indian HealthcareSeptember 30, 2026
11th National Convention on Medicine & Law 2026 Successfully Concludes at D Y Patil University, Navi MumbaiSeptember 29, 2026
Can Your Skin Show the Signs of Chronic Stress? Dermatologists Explain What to Watch ForSeptember 29, 2026
MDI Gurgaon’s Samvaad X ScaNxt NXT STEP to Put Strategic Decision-Making Under Polycrisis Conditions to TestSeptember 29, 2026
Point-of-Care Diagnostics in India: Bringing Faster Testing Closer to PatientsSeptember 29, 2026
Adult Vaccination in India: The Preventive Care Gap Beyond ChildhoodSeptember 29, 2026
Maternal Nutrition Beyond Iron and Folic Acid: What Modern Prenatal Care in India Should IncludeSeptember 29, 2026